Glucagon antagonism as a potential therapeutic target in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 11, 2011, Pages 965-971

  Bagger, J I ^a   Knop, F K ^a   Holst, J J ^b   Vilsboll T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucagon; Glucagon antagonist; Treatment; Type 2 diabetes

Indexed keywords

AMINOTHIAZOLE; ANTIDIABETIC AGENT; BAY 27995; BENZIMIDAZOLE; BI 32169; COMPOUND 1; COMPOUND 15; DIAZOXIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DSR 11759; DSR 17759; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; IMIDAZOLE; LY 2409021; MESSENGER RNA; MK 0893; MONOCLONAL ANTIBODY; NNC 250926; NNC 252504; PRAMLINTIDE; PROGLUCAGON; SKYRIN; SOMATOSTATIN; SPIROUREA; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BRAIN; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCAGON ANTAGONISM; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONAL REGULATION; HUMAN; HYPERGLUCAGONEMIA; INTESTINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS; PANCREAS ISLET CELL HYPERPLASIA; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

EID: 80053389354     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01427.x     Document Type: Review

References (82)

1. Alford FP, Bloom SR, Nabarro JD et al. Glucagon control of fasting glucose in man. Lancet 1974; 2: 974-977.
2. Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR. Control of hepatic glucose output by glucagon and insulin in the intact dog. Biochem Soc Symp 1978; 43: 31-45.
3. Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007; 28: 84-116.
4. Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med 1981; 304: 1518-1524.
5. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987; 64: 106-110.
6. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 4053-4059.
7. Knop FK, Vilsbøll T, Højberg PV et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007; 56: 1951-1959.
8. Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340-1348.
9. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007; 50: 797-805.
10. Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C. Proglucagon processing in porcine and human pancreas. J Biol Chem 1994; 269: 18827-18833.
11. Rouillé Y, Westermark G, Martin SK, Steiner DF. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proc Natl Acad Sci U S A 1994; 91: 3242-3246.
12. Ugleholdt R, Zhu X, Deacon CF, Ørskov C, Steiner DF, Holst JJ. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology 2004; 145: 1349-1355.
13. Zhu X, Zhou A, Dey A et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 2002; 99: 10293-10298.
14. Miki T, Liss B, Minami K et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 2001; 4: 507-512.
15. MacDonald PE, De Marinis YZ, Ramracheya R et al. A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biol 2007; 5: e143.
16. Vieira E, Salehi A, Gylfe E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 2007; 50: 370-379.
17. Quesada I, Tudurí E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 2008; 199: 5-19.
18. Xu E, Kumar M, Zhang Y et al. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metab 2006; 3: 47-58.
19. Winnock F, Ling Z, De Proft R et al. Correlation between GABA release from rat islet beta-cells and their metabolic state. Am J Physiol Endocrinol Metab 2002; 282: E937-E942.
20. Wang C, Kerckhofs K, Van de Casteele M, Smolders I, Pipeleers D, Ling Z. Glucose inhibits GABA release by pancreatic beta-cells through an increase in GABA shunt activity. Am J Physiol Endocrinol Metab 2006; 290: E494-E499.
21. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB. Beta-cell secretory products activate alpha-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 2005; 54: 1808-1815.
22. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-1180.
23. Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metab Clin Exp 1997; 46: 67-70.
24. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2009; 2: 203-214.
25. Silvestre RA, Rodríguez-Gallardo J, Jodka C et al. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 2001; 280: E443-E449.
26. Luft R, Efendić S, Hökfelt T. Somatostatin-both hormone and neurotransmitter? Diabetologia 1978; 14: 1-13.
27. Hauge-Evans AC, King AJ, Carmignac D et al. Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009; 58: 403-411.
28. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008; 51: 2263-2270.
29. Aaboe K, Knop FK, Vilsbøll T et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010; 12: 323-333.
30. Herman GA, Bergman A, Stevens C et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
31. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-1770.
32. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009-2013.
33. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
34. Christensen M, Knop FK, Vilsbøll T et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes mellitus. Diabetes 2009; 58: A368.
35. Meier JJ, Nauck MA, Pott A et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130: 44-54.
36. Sørensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003; 27: 450-456.
37. de Heer J, Pedersen J, Orskov C, Holst JJ. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007; 50: 2135-2142.
38. Pederson RA, Brown JC. Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas. Endocrinology 1978; 103: 610-615.
39. Meier JJ, Gallwitz B, Siepmann N et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798-801.
40. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114: 115-121.
41. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497-2504.
42. Ahrén B. Autonomic regulation of islet hormone secretion-implications for health and disease. Diabetologia 2000; 43: 393-410.
43. Jelinek LJ, Lok S, Rosenberg GB et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 1993; 259: 1614-1616.
44. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284: E671-E678.
45. Hansen LH, Abrahamsen N, Nishimura E. Glucagon receptor mRNA distribution in rat tissues. Peptides 1995; 16: 1163-1166.
46. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296: E415-E421.
47. Kieffer TJ, Heller RS, Unson CG, Weir GC, Habener JF. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 1996; 137: 5119-5125.
48. Ma X, Zhang Y, Gromada J et al. Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors. Mol Endocrinol 2005; 19: 198-212.
49. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290: 839-843.
50. Gelling RW, Du XQ, Dichmann DS et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003; 100: 1438-1443.
51. Sørensen H, Winzell MS, Brand CL et al. Glucagon receptor knockout mice display increased insulin sensitivity and impaired beta-cell function. Diabetes 2006; 55: 3463-3469.
52. Balas D, Senegas-Balas F, Delvaux M et al. Silent human pancreatic glucagonoma and "A" nesidioblastosis. Pancreas 1988; 3: 734-739.
53. Martignoni ME, Kated H, Stiegler M et al. Nesidioblastosis with glucagon-reactive islet cell hyperplasia: a case report. Pancreas 2003; 26: 402-405.
54. Yu R, Nissen NN, Dhall D, Heaney AP. Nesidioblastosis and hyperplasia of alpha cells, microglucagonoma, and nonfunctioning islet cell tumor of the pancreas: review of the literature. Pancreas 2008; 36: 428-431.
55. Zhou C, Dhall D, Nissen N, Chen C, Yu R. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 2009; 38: 941-946.
56. Hansen L, Larger E, Chaput J et al. Identification of a glucagon receptor gene deletion mutation in a patient with hyperglucagonemia and pseudo-adenomatous hyperplasia of pancreatic alpha-cells. J Clin Endocrinol Metab 1999; 84: P3-P441.
57. Liang Y, Osborne MC, Monia BP et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004; 53: 410-417.
58. Sloop KW, Cao JX-C, Siesky AM et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004; 113: 1571-1581.
59. Brand CL, Jørgensen PN, Svendsen I, Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996; 45: 1076-1083.
60. Stevenson RW, Steiner KE, Hendrick GK, Cherrington AD. Effect of somatostatin on glucose homeostasis in conscious long-fasted dogs. Am J Physiol 1987; 253: E435-E442.
61. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982; 215: 1115-1116.
62. Van Tine BA, Azizeh BY, Trivedi D et al. Low level cyclic adenosine 3', 5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 1996; 137: 3316-3322.
63. Parker JC, McPherson RK, Andrews KM et al. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 2000; 49: 2079-2086.
64. Gysin B, Johnson DG, Trivedi D, Hruby VJ. Synthesis of two glucagon antagonists: receptor binding, adenylate cyclase, and effects on blood plasma glucose levels. J Med Chem 1987; 30: 1409-1415.
65. Dallas-Yang Q, Shen X, Strowski M et al. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 2004; 501: 225-234.
66. Madsen P, Ling A, Plewe M et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2, 3, 5, 6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem 2002; 45: 5755-5775.
67. Qureshi SA, Rios Candelore M, Xie D et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004; 53: 3267-3273.
68. Shen D-M, Zhang F, Brady EJ et al. Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett 2005; 15: 4564-4569.
69. Ladouceur GH, Cook JH, Doherty EM, Schoen WR, MacDougall ML, Livingston JN. Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. Bioorg Med Chem Lett 2002; 12: 461-464.
70. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44: 2018-2024.
71. Kim RM, Chang J, Lins AR et al. Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorg Med Chem Lett 2008; 18: 3701-3705.
72. Lau J, Behrens C, Sidelmann UG et al. New beta-alanine derivatives are orally available glucagon receptor antagonists. J Med Chem 2007; 50: 113-128.
73. Yan H, Gu W, Yang J et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 2009; 329: 102-111.
74. Chang LL, Sidler KL, Cascieri MA et al. Substituted imidazoles as glucagon receptor antagonists. Bioorg Med Chem Lett 2001; 11: 2549-2553.
75. Jiang G, Brady E, Dallas-Yang Q et al. Chronic treatment with a glucagon receptor antagonist reduces blood glucose and elevates circulating GLP-1 in diet-induced obese mice. Diabetes 2009; 58: A41.
76. Mu J, Qureshi S, Brady E et al. Preclinical efficacy and mechanism of action of a potent small molecule glucagon receptor antagonist. Diabetes 2010; 59: A406.
77. Potterat O, Wagner K, Gemmecker G et al. BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp. J Nat Prod 2004; 67: 1528-1531.
78. Knappe TA, Linne U, Xie X, Marahiel MA. The glucagon receptor antagonist BI-32169 constitutes a new class of lasso peptides. FEBS Lett 2010; 584: 785-789.
79. Gu W, Yan H, Winters KA et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 2009; 331: 871-881.
80. Hirata T, Matsumoto T, Kato H, Tsuji J, Hiramatsu R. DSR-17759, a novel glucagon receptor antagonist, improves hyperglycemia without affecting plasma insulin level and provides a new approach to combination therapy for type 2 diabetes. Diabetes 2010; 59: A105.
81. Rivera N, Everett-Grueter CA, Edgerton DS et al. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther 2007; 321: 743-752.
82. Madsen P, Kodra JT, Behrens C et al. Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. J Med Chem 2009; 52: 2989-3000.